We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Biological Markers in Tears May Diagnose PD

By LabMedica International staff writers
Posted on 15 Mar 2018
Print article
Image: The Schirmer’s test is an invasive filter paper strip folded over the lower lid to absorb the tear film for five minutes. The tears collected on the Schirmer’s strips can be analyzed for biomarkers (Photo courtesy of Innovative Eye Care).
Image: The Schirmer’s test is an invasive filter paper strip folded over the lower lid to absorb the tear film for five minutes. The tears collected on the Schirmer’s strips can be analyzed for biomarkers (Photo courtesy of Innovative Eye Care).
Parkinson's disease is a progressive disorder that kills brain cells that produce dopamine, which is a chemical messenger important for the control of movement. The main symptoms of Parkinson's include slowness of movement, tremors, rigidity, and difficulty maintaining balance and coordination.

Tear samples from individuals with Parkinson's disease (PD) had different levels of a protein linked to the disease than those who did not have it. Such a marker could be very useful in helping to diagnose, and perhaps even treat Parkinson's because the disease can begin many years before its symptoms appear.

Scientists at the University of Southern California (Los Angeles, CA, USA) and their colleagues compared tear samples from 55 PD patients of varying severity and 27 age- and gender-matched non-PD controls were collected and pooled from both eyes for analysis of alpha synuclein, CC chemokine ligand 2 (CCL-2) and DJ-1 (Parkinson’s disease protein 7) using a Human magnetic Luminex assay kit and analysis of oligomeric alpha-synuclein using an Human alpha-synuclein oligo enzyme-linked immunosorbent assay (ELISA) kit, respectively.

The team revealed that total alpha-synuclein decreased significantly in PD patients (423.12 ± 52.6 pg/mg tear protein) relative to healthy controls (703.61 ± 136.4 pg/mg tear protein) in tears from patients acquired from Schirmer’s strips taken during an anesthetized Schirmer’s test. Oligomeric alpha-synuclein increased significantly in PD patients (1.45 ± 0.31 ng/mg tear protein) relative to controls (0.27 ± 0.07 ng/mg tear protein). While detectable in tears, neither CCL-2 nor DJ-1 varied between PD patients and non-PD controls.

While it is not yet clear how Parkinson's disease kills brain cells, scientists have discovered that toxic protein deposits known as Lewy bodies are often present in many brain cells of people with the disease. These deposits contain clusters of proteins that have not folded correctly. A major component of Lewy bodies is an oligomeric form of the protein alpha-synuclein. The oligomeric form of a protein comprises several repeats of the protein's essential amino acids, but not as many as the polymeric form. An author of a recently published study of alpha-synuclein in Parkinson's has suggested that the oligomeric protein's ability to "disrupt the integrity of the membrane" might be a key step in the process that ultimately kills the cell.

Mark F. Lew, MD, a professor of Neurology and lead investigator in the study, said, “We believe our study is the first to show that tears may be a reliable, inexpensive, and noninvasive biological marker of Parkinson's disease.” The study will be presented at the 70th annual meeting of the American Academy of Neurology, which will be held April 21-27, 2018, in Los Angeles, CA, USA.

Related Links:
University of Southern California

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.